FzioMed marked the sale of 500,000 units of its Oxiplex® viscoelastic hydrogel worldwide. This is an increase from 400,000 units sold, as reported in July 2015.
Oxiplex is approved for sale in >70 countries ex-U.S., and distributed under brand names of Oxiplex, Oxiplex/SP, MediShield and Interpose. The absorbable gel is applied to neural tissues following spine surgery, making a temporary barrier between adjacent tissues. The gel has been shown in peer-reviewed studies to reduce leg pain, back pain and neurologic symptoms.
FzioMed marked the sale of 500,000 units of its Oxiplex® viscoelastic hydrogel worldwide. This is an increase from 400,000 units sold, as reported in July 2015.
Oxiplex is approved for sale in >70 countries ex-U.S., and distributed under brand names of Oxiplex, Oxiplex/SP, MediShield and Interpose. The absorbable gel is applied to neural...
FzioMed marked the sale of 500,000 units of its Oxiplex® viscoelastic hydrogel worldwide. This is an increase from 400,000 units sold, as reported in July 2015.
Oxiplex is approved for sale in >70 countries ex-U.S., and distributed under brand names of Oxiplex, Oxiplex/SP, MediShield and Interpose. The absorbable gel is applied to neural tissues following spine surgery, making a temporary barrier between adjacent tissues. The gel has been shown in peer-reviewed studies to reduce leg pain, back pain and neurologic symptoms.
Copy to clipboard 
